Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinomain vitro
Open Access
- 1 January 2011
- journal article
- Published by Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy in Journal of Gynecologic Oncology
- Vol. 22 (4) , 225-232
Abstract
Bilir A, et al. J Gynecol Oncol. 2011 Dec;22(4):225-232. http://dx.doi.org/10.3802/jgo.2011.22.4.225Keywords
This publication has 26 references indexed in Scilit:
- Lithium reduces tumorigenic potential in response to EGF signaling in human colorectal cancer cellsInternational Journal of Oncology, 2011
- Progesterone: the ultimate endometrial tumor suppressorTrends in Endocrinology & Metabolism, 2011
- A Novel Signaling Axis of Matriptase/PDGF-D/β-PDGFR in Human Prostate CancerCancer Research, 2010
- Cell Death Mechanisms and Their Implications in ToxicologyToxicological Sciences, 2010
- A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid CancerThyroid®, 2010
- Constitutive activation of glycogen synthase kinase-3β correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancerBMC Gastroenterology, 2010
- Serum Midkine Correlates with Tumor Progression and Imatinib Response in Gastrointestinal Stromal TumorsAnnals of Surgical Oncology, 2010
- Progestogen treatment options for early endometrial cancerBJOG: An International Journal of Obstetrics & Gynaecology, 2010
- Carvedilol in glioma treatment alone and with imatinib in vitroInternational Journal of Oncology, 2010
- Medroxyprogesterone acetate in the management of cancer cachexiaExpert Opinion on Pharmacotherapy, 2009